Inoviq Ltd (AU:IIQ)
ASX:IIQ
IIQ Stock Chart & Stats
AU$0.40
AU$0.02(3.09%)
At close: 4:00 PM EST
AU$0.40
AU$0.02(3.09%)
Day’s Range― - ―
52-Week RangeAU$0.32 - AU$0.69
Previous CloseN/A
Volume76.26K
Average Volume (3M)196.06K
Market Cap
AU$48.57M
Enterprise ValueAU$26.77M
Total Cash (Recent Filing)AU$13.80M
Total Debt (Recent Filing)AU$270.31K
Price to Earnings (P/E)―
Beta0.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,775,450
10 Day Avg. Volume262,451
30 Day Avg. Volume196,057
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.46
Price to Sales (P/S)22.67
P/FCF Ratio-8.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA very low debt-to-equity ratio provides durable financial flexibility and low fixed interest burden, reducing default risk and preserving capacity to fund R&D or clinical programs via equity or grants rather than servicing high debt. This supports long-term optionality in a capital-intensive sector.
Lean Operating FootprintA small, focused headcount indicates a lean cost base that can stretch limited cash while outsourcing specialized lab work. Over a multi-month horizon this conserves runway, supports disciplined cash deployment into clinical validation and enables scalable external partnerships without large fixed overheads.
Oncology Diagnostics Platform FocusConcentration on exosome diagnostics and immuno-oncology targets enduring, high-demand clinical areas with structural growth and unmet needs. As a platform, technologies can generate multiple product opportunities and recurring clinical/partnering revenue streams, offering long-term commercial optionality.
Bears Say
Persistent UnprofitabilitySustained negative margins and reported recent revenue decline hinder internal reinvestment and commercial scaling. Over the medium term this forces reliance on external funding, constrains clinical program expansion, and weakens negotiating leverage with partners and customers.
Weak Cash GenerationConsistent negative operating and free cash flow depletes liquidity and shortens runway for clinical validation and commercialization. This structural cash weakness increases probability of future equity raises or partnerships on unfavorable terms, diluting shareholders and slowing strategic progress.
Poor Capital EfficiencyA markedly negative ROE signals that invested equity is not generating returns, reflecting ineffective capital allocation or failed commercialization. Over months this undermines investor confidence, raises cost of capital, and makes securing growth funding or high-quality partnerships more difficult.
Inoviq Ltd News
IIQ FAQ
What was Inoviq Ltd’s price range in the past 12 months?
Inoviq Ltd lowest share price was AU$0.32 and its highest was AU$0.69 in the past 12 months.
What is Inoviq Ltd’s market cap?
Inoviq Ltd’s market cap is AU$48.57M.
When is Inoviq Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Inoviq Ltd’s earnings last quarter?
Currently, no data Available
Is Inoviq Ltd overvalued?
According to Wall Street analysts Inoviq Ltd’s price is currently Overvalued.
Does Inoviq Ltd pay dividends?
Inoviq Ltd does not currently pay dividends.
What is Inoviq Ltd’s EPS estimate?
Inoviq Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inoviq Ltd have?
Inoviq Ltd has 140,775,450 shares outstanding.
What happened to Inoviq Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inoviq Ltd?
Currently, no hedge funds are holding shares in AU:IIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inoviq Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IIQ Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$122.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.83%
12-Months-Change
Fundamentals
Return on Equity
-37.14%
Trailing 12-Months
Asset Growth
15.77%
Trailing 12-Months
Company Description
Inoviq Ltd
INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Options Prices
Currently, No data available
---